Combining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
Peptide receptor radionuclide therapy (PRRT) just got more interesting for pancreatic cancer research. A UC Davis team tested a combo punch: an αvβ6-targeted lutetium-177-labeled peptide, paired with the PARP inhibitor olaparib. Their goal? Hit hard-to-treat pancreatic tumors from two angles and see if the results stacked up.
J Nucl Med
by Ganguly T, Harris RE, Hausner SH et al.
“Combining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer. Ganguly T(1), Harris RE(2), Hausner SH(2), Sutcliffe JL(3)(2)(4). Author information: (1)Department Biomedical Engineering, University of California Davis, Davis, California. (2)Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis, Sacramento, California; and. (3)Department Biomedical Engineering, University of California Davis, Davis, California; jlsutcliffe@health.ucdavis.edu. (4)Center for Molecular and Genomic Imaging, University of California Davis, Davis, California. Pancreatic ductal adenocarcinoma is one of the most lethal malignances worldwide, and there remains an urgent need for more effective and less toxic treatment strategies. Integrin αvβ6 is a cell-surface receptor that is overexpressed in several malignancies, including pancreatic ductal adenocarcinoma, and plays a key role in invasion and metastasis, making it a promising molecular target for the detection and treatment of many cancers. We investigated a molecularly targeted approach that exploits the overexpression of αvβ6 using peptide receptor radionuclide therapy (PRRT) in combination with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib. Methods: We combined the αvβ6-targeted PRRT agent [177Lu]Lu-DOTA-ABM-5G with olaparib, a PARP inhibitor. The combination therapy was evaluated in vitro in αvβ6-positive pancreatic Capan-1 cells by investigating its effect on cell viability, apoptosis induction, cell cycle arrest, and the formation of double-strand breaks. In vivo pharmacokinetic and therapeutic efficacy studies were performed in mice bearing Capan-1 xenograft tumors. Results: In vitro, the [177Lu]Lu-DOTA-ABM-5G was rapidly internalized by αvβ6-positive pancreatic Capan-1 cells; in vivo, it was taken up by Capan-1 xenograft tumors in mice. Combination treatment with [177Lu]Lu-DOTA-ABM-5G and olaparib significantly reduced cell viability (water-soluble tetrazolium salt 1 assay), significantly increased the percentage of cells in the sub-G1 and G2/M phases (cell cycle analysis), and resulted in the greatest number of γ-H2AX foci per cell compared with single-agent treatment. In vivo, the combination treatment delayed tumor growth progression and significantly improved median survival compared with the control and single-agent treatments, with no observed treatment-related adverse events. Conclusion: The combination of αvβ6-targeted PRRT and PARP inhibition enhanced therapeutic efficacy compared with single-agent treatment. These findings warrant further investigation, particularly given the urgent need for improved treatments for pancreatic cancer. © 2026 by the Society of Nuclear Medicine and Molecular Imaging.”
Here’s what went down:
The peptide, [177Lu]Lu-DOTA-ABM-5G, was designed to target integrin αvβ6 — a receptor overexpressed in pancreatic ductal adenocarcinoma and other aggressive cancers.
In vitro, this peptide was quickly internalized by αvβ6-positive cancer cells. When combined with olaparib, cell viability tanked, cell cycle arrest ramped up, and DNA double-strand breaks shot through the roof.
In mice, the combo delayed tumor growth and boosted median survival compared to either agent alone. Zero observed toxicity.
Key takeaway: Pairing an αvβ6-targeted radiolabeled peptide with a PARP inhibitor amplifies anti-tumor effects. The synergy here is clear — cells get hit with DNA damage from two sides, leading to more apoptosis and less tumor progression.
Why does this matter for peptide researchers? It’s a strong case for combinatorial approaches. Peptide-based therapeutics can be dialed in for specific tumor markers, and stacking them with small molecule inhibitors like olaparib could be a smart way forward, especially in research models where single-agent efficacy stalls.
If you’re tracking the next wave of targeted oncology research, this is one to watch. For more on where peptide research is headed, check the peptide research index. And if you’re sourcing or comparing research compounds, the vendor directory is worth a look.
Combination strategies like this are what keep the peptide field moving.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · Oral Surg Oral Med Oral Pathol Oral RadiolOrofacial adverse events associated with Glucagon-like peptide-1 receptor agonists: a real-world multinational retrospective matched cohort study.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.